Press Room

Drug Delivery to the Lungs - DDL25

Start
Wednesday, December 10, 2014 - 00:00
End
Friday, December 12, 2014 - 00:00
Location: Edinburgh, Scotland, UK
Booth Number: 36 A



DDL25 will be held from Wednesday 10th December until Friday 12th December 2014 at the Edinburgh International Conference Centre, Edinburgh, Scotland, UK. Hovione will be present with a booth (36 A) and a set of posters.

Contact us if you would like to schedule a meeting or to find more about the Hovione posters at DDL.

contact us button | Hovione



 



HOVIONE POSTERS

Respiratory targeting: Drug-alone Formulations enabled by Particle Engineering

Nick Barker, Gaauri Naik, Sofia Silva & Eunice Costa

Screening and Optimization of Formulation and Process Parameters for the Manufacture of Inhalable Composite Particles by Spray-drying

Cláudia Moura, João Vicente, Maria Palha, Filipe Neves, Ana Aguiar-Ricardo & Eunice Costa

On the performance of coarse and fine lactose blends for DPIs: Part A – rheology behavior

Filipa M. Maia, Maria Palha, Isabel S. Lopes & Filipe Neves

On the performance of coarse and fine lactose blends for DPIs: Part B - capsule filling and device performance

Maria Palha, Filipa M. Maia, João V. Fernandes & Filipe Neves

The Influence of the Formulation and Delivery Approach on the Aerodynamic Performance of Salmeterol Xinafoate

Cláudia Moura, Sofia Silva, Filipe Neves, Ana Aguiar-Ricardo & Eunice Costa

 

DOWNLOAD POSTERS

The posters will be available after the conference and by pre-registration only. To assure that you get your copy, complete the pre-registration below.

pre-register button | Hovione

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026